Preclinical research is exploring both preventive and treatment applications of TTX-001, with the goal of addressing fibrosis before it becomes established as well as reversing damage already underway, a critical capability in acute exposure scenarios.
Activity has been demonstrated in multiple cell-based models, in human lung and skin fibrotic tissue ex vivo, and in murine lung fibrosis models, supporting advancement of the platform toward clinical investigation in exposure-induced fibrosis.
TTX-001 is a peptide being developed with oral bioavailability as a target route of administration, with the goal of enabling practical deployment across the range of settings where exposure-induced fibrosis presents as a clinical challenge.